Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Owens, D. R.
Right arrow Articles by Kurzhals, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Owens, D. R.
Right arrow Articles by Kurzhals, R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 23, Issue 6 813-819, Copyright © 2000 by American Diabetes Association

ARTICLES

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites

DR Owens, PA Coates, SD Luzio, JP Tinbergen and R Kurzhals
University of Wales College of Medicine, Diabetes Research Unit, Academic Centre, Llandough Hospital, Penarth, South Glamorgan, UK.

OBJECTIVE: To determine the subcutaneous absorption rates and the appearance in plasma of 3 formulations of the long-acting human insulin analog insulin glargine (HOE 901) differing only in zinc content (15, 30, and 80 microg/ml). RESEARCH DESIGN AND METHODS: We conducted 2 studies. Study 1 compared the subcutaneous abdominal injection of 0.15 U/kg of 125I-labeled insulin glargine[15], insulin glargine[80], NPH insulin, and placebo. In study 2, 0.2 U/kg of insulin glargine[30] was injected into the arm, leg, and abdominal regions. Both studies had a randomized crossover design; each enrolled 12 healthy men, aged 18-50 years. RESULTS: In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001). Mean residual radioactivity with NPH insulin was also significantly lower at 24 h (21.9 vs. 43.8 and 52.2%, P < 0.0001). The calculated plasma exogenous insulin concentrations after NPH insulin were substantially higher than those with insulin glargine, reaching a peak within the first 6 h after administration before declining. Insulin glargine, however, did not exhibit a distinct peak. Weighted average plasma glucose concentration between 0 and 6 h was significantly lower after NPH compared with insulin glargine (P < 0.001). In study 2, there were no significant differences in the absorption characteristics of insulin glargine between the 3 injection sites (T75% = 11.9, 15.3, and 13.2 h for arm, leg, and abdomen, respectively) or in residual radioactivity at 24 h. CONCLUSIONS: Subcutaneous absorption of insulin glargine is delayed compared with NPH insulin. There is little or no difference in the absorption rate of insulin glargine between the main subcutaneous injection sites.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
T. Linn, B. Fischer, N. Soydan, M. Eckhard, J. Ehl, C. Kunz, and R. G. Bretzel
Nocturnal Glucose Metabolism after Bedtime Injection of Insulin Glargine or Neutral Protamine Hagedorn Insulin in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3839 - 3846.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
I. Hartman
Insulin Analogs: Impact on Treatment Success, Satisfaction, Quality of Life, and Adherence
Clin. Med. Res., September 1, 2008; 6(2): 54 - 67.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. Kota, K. K. Machavaram, D. N. McLennan, G. A. Edwards, C. J. H. Porter, and S. A. Charman
Lymphatic Absorption of Subcutaneously Administered Proteins: Influence of Different Injection Sites on the Absorption of Darbepoetin Alfa Using a Sheep Model
Drug Metab. Dispos., December 1, 2007; 35(12): 2211 - 2217.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
F. Porcellati, P. Rossetti, N. B. Ricci, S. Pampanelli, E. Torlone, S. H. Campos, A. M. Andreoli, G. B. Bolli, and C. G. Fanelli
Pharmacokinetics and Pharmacodynamics of the Long-Acting Insulin Analog Glargine After 1 Week of Use Compared With Its First Administration in Subjects With Type 1 Diabetes
Diabetes Care, May 1, 2007; 30(5): 1261 - 1263.
[Full Text] [PDF]

Home page
 EDUCATION AND PRACTICEHome page
F. M Regan and D. B Dunger
Use of new insulins in children
Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Plank, M. Bodenlenz, F. Sinner, C. Magnes, E. Gorzer, W. Regittnig, L. A. Endahl, E. Draeger, M. Zdravkovic, and T. R. Pieber
A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir
Diabetes Care, May 1, 2005; 28(5): 1107 - 1112.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Rosenstock, G. Dailey, M. Massi-Benedetti, A. Fritsche, Z. Lin, and A. Salzman
Reduced Hypoglycemia Risk With Insulin Glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes
Diabetes Care, April 1, 2005; 28(4): 950 - 955.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. Peter, S. D. Luzio, G. Dunseath, A. Miles, B. Hare, K. Backx, V. Pauvaday, and D. R. Owens
Effects of Exercise on the Absorption of Insulin Glargine in Patients With Type 1 Diabetes
Diabetes Care, March 1, 2005; 28(3): 560 - 565.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
I. B. Hirsch
Insulin Analogues
N. Engl. J. Med., January 13, 2005; 352(2): 174 - 183.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
P. Home, P. Bartley, D. Russell-Jones, H. Hanaire-Broutin, J.-E. Heeg, P. Abrams, M. Landin-Olsson, B. Hylleberg, H. Lang, and E. Draeger
Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes: A randomized clinical trial
Diabetes Care, May 1, 2004; 27(5): 1081 - 1087.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
T. Danne, K. Lupke, K. Walte, W. von Schuetz, and M.-A. Gall
Insulin Detemir Is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes
Diabetes Care, November 1, 2003; 26(11): 3087 - 3092.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
R. Gadsby
Using insulin earlier in the treatment of type 2 diabetes
The British Journal of Diabetes & Vascular Disease, March 1, 2003; 3(2): 119 - 122.
[Abstract] [PDF]

Home page
 Endocr. Rev.Home page
Z. Vajo, J. Fawcett, and W. C. Duckworth
Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs
Endocr. Rev., October 1, 2001; 22(5): 706 - 717.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2000 by the American Diabetes Association.